A new genetic test developed in Nottingham can identify brain tumour types in just 90 minutes—down from weeks. This rapid diagnosis means surgeons can tailor surgery immediately, start treatments sooner, and reduce patient anxiety. Several NHS hospitals are now adopting this game-changing technology.
A Game-Changing Breakthrough in Brain Tumour Diagnosis
A new genetic test developed in Nottingham is set to transform how brain tumours are diagnosed and treated across the UK. This ultra-rapid method can identify the exact type of brain tumour in as little as 90 minutes—cutting down the usual wait from several weeks to just hours.
Faster, Smarter Diagnosis
Traditionally, tumour samples are sent away for lab analysis, which can take up to eight weeks. This delay sometimes means patients need additional surgeries if the first operation wasn’t tailored to the tumour type. The new test uses advanced nanopore DNA sequencing and smart software to analyse tumour DNA in real time—even while the patient is still in surgery.
This means surgeons can adjust their approach immediately, removing more tissue if needed or avoiding unnecessary procedures. Faster diagnosis also means patients can start treatments like chemotherapy or radiotherapy sooner, improving outcomes and reducing anxiety.
Real Benefits for Patients and Families
For many families, waiting weeks for a diagnosis is a stressful and uncertain time. This rapid test can spare patients from extra surgeries and provide clarity sooner, helping them and their care teams make informed decisions quickly.
Proven Success and Wider Adoption
Already used successfully in 50 operations, this test has achieved a 100% success rate in accurately diagnosing tumour types. It’s faster, more accurate, and more cost-effective than traditional methods. Several NHS hospitals across the country are now adopting this technology to bring these benefits to more patients.
Looking Ahead
This breakthrough is a huge step forward in brain tumour care. By delivering rapid, accurate diagnoses, it supports personalised treatment plans and opens doors to clinical trials for patients everywhere. Faster answers, better treatment, and greater peace of mind—this new test is a real game changer for brain tumour patients and their families.